6
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

      Submit here before May 31, 2024

      About Oncology Research and Treatment: 2.4 Impact Factor I 3.3 CiteScore I 0.495 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Rituximab Twice Weekly for Refractory Thrombotic Thrombocytopenic Purpura in a Critically Ill Patient with Acute Respiratory Distress Syndrome

      case-report

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Thrombotic thrombocytopenic purpura (TTP) is a rare, serious, life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and hypercoagulability. The etiology is a deficiency of ADAMTS13 which is usually caused by acquired antibodies. Plasma exchange and steroids is the standard of care in the treatment of TTP. However, there are refractory cases of TTP which require further management. Rituximab appears to be a safe and effective therapy for refractory and relapsing TTP. Here we report a challenging case of TTP that responded to treatment with rituximab twice weekly. According to our knowledge, rituximab twice weekly has never been used for TTP before.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: not found
          • Article: not found

          Acute respiratory distress syndrome and non-occlusive mesenteric ischemia as major clinical manifestations of thrombotic thrombocytopenic purpura: complete remission following exchange plasmapheresis.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              and Blood Institute (NHLBI). Thrombotic thrombocytopenic purpura

                Bookmark

                Author and article information

                Journal
                CRO
                CRO
                10.1159/issn.1662-6575
                Case Reports in Oncology
                S. Karger AG
                1662-6575
                2020
                January – April 2020
                17 February 2020
                : 13
                : 1
                : 153-157
                Affiliations
                [_a] aDepartment of Medical Education, Hamad Medical Corporation, Doha, Qatar
                [_b] bNational Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
                Author notes
                *Bahjat Azrieh, MD, Hamad Medical Corporation, Bayti 4 Bldg., Khor Shaquiq St, Al Sadd, Doha (Qatar), BAzrieh@hamad.qa
                Article
                505236 Case Rep Oncol 2020;13:153–157
                10.1159/000505236
                1876f428-9fec-44a9-bdb4-eaaf3f9f87d4
                © 2020 The Author(s) Published by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 25 November 2019
                : 28 November 2019
                Page count
                Pages: 5
                Categories
                Case Report

                Oncology & Radiotherapy,Pathology,Surgery,Obstetrics & Gynecology,Pharmacology & Pharmaceutical medicine,Hematology
                Platelet disorder,Thrombotic thrombocytopenic purpura,Rituximab,Refractory disease,Relapse,Thrombocytopenia

                Comments

                Comment on this article